Neurology · Pain ManagementRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for FIORICET with Codeine

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/25/2026, 12:34:19 AM

Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for FIORICET with Codeine is a significant regulatory milestone that could strengthen Actavis' competitive position in the pain management sector. Portfolio teams must evaluate the potential market impact and prepare to respond to competitive pressures from similar products. Regulatory context from FDA (FDA AP — FIORICET W/ CODEINE (SUPPL)) supports the near-term read. Assessment grounded in 4 ranked evidence items (1 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and consider strategies to counteract potential competitive advantages. The strongest clinical anchor is Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management (ClinicalTrials.gov), sub-indication match (pain). In pain, 1 regulatory and 0 competitive items passed relevance filtering for Actavis Labs.

Competitive Pressure

The most relevant competitive pressure comes from This acceptance may enhance Actavis' position in the pain management market, potentially impacting competitors offering similar formulations..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — FIORICET W/ CODEINE (SUPPL) (FDA). Entity match (actavis labs). While the acceptance is a positive step, the final approval decision and subsequent market launch will be critical in determining the full regulatory implications.

Key Risks

Elevated medium regulatory exposure for Actavis Labs could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to increased market share for Actavis in pain management, affecting revenue streams for competitors with similar offerings.
Portfolio teams should assess the implications of this approval on market share and consider strategies to counteract potential competitive advantages.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval decision and any subsequent market launch timelines.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — FIORICET W/ CODEINE (SUPPL)
FDAmedium relevance
Entity match (actavis labs)
FDA document
View source
FDA AP — CODEINE SULFATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — CODEINE SULFATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
FDA Grants Approval for Eltrombopag Olamine ANDA208815
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Actavis Labs
FIORICET with Codeine
competitors offering similar formulations

Commercial impact

medium

The approval could lead to increased market share for Actavis in pain management, affecting revenue streams for competitors with similar offerings.

Regulatory impact

medium

While the acceptance is a positive step, the final approval decision and subsequent market launch will be critical in determining the full regulatory implications.

What to watch

Monitor for the final approval decision and any subsequent market launch timelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.